Please login to the form below

Not currently logged in
Email:
Password:

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

GalapagosJanssen and Galapagos have mutually agreed to terminate their inflammation alliance and option agreements. 

Alongside other candidates, Galapagos will obtain all rights to drug GLPG1690, a selective autotaxin inhibitor preparing for phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterised by a progressive decline in lung function. 

Dr Piet Wigerinck, chief scientific officer at Galapagos, commented: “We are pleased to regain the rights to GLPG1690 to pursue the most suitable clinical application of autotaxin inhibition. 

“The alliance with Janssen has been underway since October 2007 and has generated three clinical molecules, two of which are now proprietary phase II assets of Galapagos: GLPG1205 and GLPG1690. This programme is a valuable component of our development portfolio and regaining the rights is a next step in our transformation into a mature biotech company with a proprietary product pipeline.”

Galapagos identified autotaxin as having a key role to play in inflammation with additional studies suggesting it may also be significant against metabolic disease, arthritic pain, oncology and lung disease. 

Article by
Kirstie Pickering

18th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics